Nanoparticles in Leukemia: Current and novel theranostic approaches D e m o c r i t u s U n i v e r s i t y o f T h r a c e , D e p a r t m e n t o f M o l e c u l a r B i o l o g y a n d G e n e t i c s S u p e r v i s o r : D r . I o a n n a M a r o u l a k o u Co-S u p e r v i s o r : P a u l A g i a n i a n , A s s t . P r o f e s s o r A l e x a n d r o u p o l i 1 0 / 1 / 2 0 1 7 Athanasios C. Gerakopoulos Cancer is the leading cause of death worldwide, with an increase in cases expected

more »

... ithin the next years. Current therapeutic and diagnostic protocols lack efficacy and/or specificity, highlighting the importance of new methods needed. Nanoparticles have received increased attention over the last years due to their huge potential in improving both diagnosis and treatment of malignancies. In this review, we focus on the application of nanoparticles in treatment and diagnosis of leukemia. Moreover, we summarize the nanoformulations that already received FDA-approval for leukemia treatment, as well as a number of novel theranostic nanosystems currently being evaluated.